Research
I lead a team within Oncology R&D at MedImmune, which is the global biologics arm of AstraZeneca. The focus of my work is on antibody therapeutics that enhance immune responses to cancer, primarily through activation of T cells. I work on a range of programs from early target assessment through to clinical development.
Publications
Hooijkaas A, Gadiot J, Morrow M, Stewart R, Schumacher T, Blank CU Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. Oncoimmunology. 2012 Aug 1;1(5):609-617.
Stewart R, Thom G, Levens M, Güler-Gane G, Holgate R, Rudd PM, Webster C, Jermutus L, Lund J. A variant human IgG1-Fc mediates improved ADCC.
Protein Eng Des Sel. 2011 Sep;24(9):671-8.
Bornstein GG, Quéva C, Tabrizi M, van Abbema A, Chavez C, Wang P, Foord O, Ahluwalia K, Laing N, Raja S, Wen S, Green LL, Yang X, Webster C, Stewart R, Blakey D. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Invest New Drugs. 2010 Oct;28(5):561-74.
